PMID- 31427226
OWN - NLM
STAT- MEDLINE
DCOM- 20210120
LR  - 20210120
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 29
IP  - 6
DP  - 2020 Jun
TI  - Single-Centre Experience of Surgical Myectomy for Hypertrophic Obstructive 
      Cardiomyopathy.
PG  - 949-955
LID - S1443-9506(19)31372-1 [pii]
LID - 10.1016/j.hlc.2019.07.009 [doi]
AB  - BACKGROUND: Septal myectomy is the gold standard treatment for hypertrophic 
      obstructive cardiomyopathy. This study aimed to evaluate the results from 
      patients with hypertrophic cardiomyopathy who had undergone septal myectomy. 
      METHODS: Data were analysed that has been prospectively collected over 7 years 
      from 345 patients with hypertrophic cardiomyopathy who underwent septal myectomy 
      at Meshalkin National Medical Research Center. RESULTS: Six (6) patients (1.7%) 
      died within 30 days of surgery. The mean (standard deviation, SD) resting left 
      ventricular outflow tract gradients reduced from 83.4 (24.2) mmHg preoperatively 
      to 16.2 (8.5) mmHg at discharge (p < 0.001). Of the 345 patients, 329 (95.4%) 
      attended the most recent follow-up assessments, and of these, 254 (77.2%) were 
      categorised as New York Heart Association (NYHA) class I, 64 (19.5%) class II, 
      and 11 (3.3%) class III. The mean overall long-term survival rate after septal 
      myectomy was 95.7% (SD 1.7%) (95% CI, 90.0-97.9). This did not differ from the 
      age-matched and gender-matched general population (log-rank, p = 0.109). At the 
      last follow-up assessments, six of 67 patients who had undergone concomitant 
      Cox-Maze IV procedures had late atrial tachyarrhythmia recurrences. A 
      preoperative short-axis view of left atrial diameter of 57.5 mm (hazard ratio, 
      1.30 (95% CI, 1.03-1.65), p < 0.001) predicted late atrial tachyarrhythmias 
      (p < 0.002). CONCLUSIONS: At this hypertrophic cardiomyopathy centre, septal 
      myectomy is associated with low operative and early mortality rates (<2%), a low 
      risk of early adverse events, and acceptable intermediate-term clinical and 
      haemodynamic results.
CI  - Copyright (c) 2019 Australian and New Zealand Society of Cardiac and Thoracic 
      Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). 
      Published by Elsevier B.V. All rights reserved.
FAU - Afanasyev, Alexander V
AU  - Afanasyev AV
AD  - Heart Valve Surgery Department, Meshalkin National Medical Research Center, 
      Novosibirsk, Russian Federation. Electronic address: av.afanasyev@icloud.com.
FAU - Bogachev-Prokophiev, Alexander V
AU  - Bogachev-Prokophiev AV
AD  - Heart Valve Surgery Department, Meshalkin National Medical Research Center, 
      Novosibirsk, Russian Federation.
FAU - Ovcharov, Michail A
AU  - Ovcharov MA
AD  - Heart Valve Surgery Department, Meshalkin National Medical Research Center, 
      Novosibirsk, Russian Federation.
FAU - Pivkin, Alexey N
AU  - Pivkin AN
AD  - Heart Valve Surgery Department, Meshalkin National Medical Research Center, 
      Novosibirsk, Russian Federation.
FAU - Zalesov, Anton S
AU  - Zalesov AS
AD  - Heart Valve Surgery Department, Meshalkin National Medical Research Center, 
      Novosibirsk, Russian Federation.
FAU - Budagaev, Sergei A
AU  - Budagaev SA
AD  - Heart Valve Surgery Department, Meshalkin National Medical Research Center, 
      Novosibirsk, Russian Federation.
FAU - Sharifulin, Ravil M
AU  - Sharifulin RM
AD  - Heart Valve Surgery Department, Meshalkin National Medical Research Center, 
      Novosibirsk, Russian Federation.
FAU - Zheleznev, Sergei I
AU  - Zheleznev SI
AD  - Heart Valve Surgery Department, Meshalkin National Medical Research Center, 
      Novosibirsk, Russian Federation.
FAU - Karaskov, Alexander M
AU  - Karaskov AM
AD  - Heart Valve Surgery Department, Meshalkin National Medical Research Center, 
      Novosibirsk, Russian Federation.
LA  - eng
PT  - Journal Article
DEP - 20190808
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
SB  - IM
MH  - Cardiac Surgical Procedures/*methods
MH  - Cardiomyopathy, Hypertrophic/diagnosis/mortality/*surgery
MH  - Echocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Septum/diagnostic imaging/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Russia/epidemiology
MH  - Survival Rate/trends
MH  - Time Factors
OTO - NOTNLM
OT  - Hypertrophic cardiomyopathy
OT  - Left ventricular outflow tract obstruction
OT  - Myectomy
EDAT- 2019/08/21 06:00
MHDA- 2021/01/21 06:00
CRDT- 2019/08/21 06:00
PHST- 2019/05/20 00:00 [received]
PHST- 2019/06/18 00:00 [revised]
PHST- 2019/07/05 00:00 [accepted]
PHST- 2019/08/21 06:00 [pubmed]
PHST- 2021/01/21 06:00 [medline]
PHST- 2019/08/21 06:00 [entrez]
AID - S1443-9506(19)31372-1 [pii]
AID - 10.1016/j.hlc.2019.07.009 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2020 Jun;29(6):949-955. doi: 10.1016/j.hlc.2019.07.009. Epub 
      2019 Aug 8.